Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Death or cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Mortality due to bleeding ‐ not reported · women diagnosed with primary PPH following vaginal birth. PPH was defined as quote: "blood loss > 500mL after delivery" p 601
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hysterectomy to control bleeding · women diagnosed with primary PPH following vaginal birth. PPH was defined as quote: "blood loss > 500mL after delivery" p 601
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious maternal morbidity (renal or respiratory failure, cardiac arrest or multiple organ failure) ‐ not reported · women diagnosed with primary PPH following vaginal birth. PPH was defined as quote: "blood loss > 500mL after delivery" p 601
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood loss > 1000 mL · women diagnosed with primary PPH following vaginal birth. PPH was defined as quote: "blood loss > 500mL after delivery" p 601
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean blood loss (mL) (trialist defined) · women diagnosed with primary PPH following vaginal birth. PPH was defined as quote: "blood loss > 500mL after delivery" p 601
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion (red cell or whole blood) · women diagnosed with primary PPH following vaginal birth. PPH was defined as quote: "blood loss > 500mL after delivery" p 601
It is very uncertain whether external uterine compression (all methods) plus normal care changes blood transfusion (red cell or whole blood) compared with normal care (very low certainty).
1 finding from 1 review
Side effects of the intervention (e.g. trauma, necrosis) ‐ not reported · women diagnosed with primary PPH following vaginal birth. PPH was defined as quote: "blood loss > 500mL after delivery" p 601
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with diabetes and foot ulcers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of any new foot ulcers · people with diabetes and foot ulcers
It is very uncertain whether arginine, glutamine and β‐hydroxy‐β‐methylbutyrate supplement changes development of any new foot ulcers compared with placebo (very low certainty).
1 finding from 1 review
Amputation · people with diabetes and foot ulcers
It is very uncertain whether arginine, glutamine and β‐hydroxy‐β‐methylbutyrate supplement changes amputation rate compared with placebo (very low certainty).
1 finding from 1 review
Quality of life · people with diabetes and foot ulcers
It is very uncertain whether arginine, glutamine and β‐hydroxy‐β‐methylbutyrate supplement changes quality of life compared with placebo (very low certainty).
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in pulmonary exacerbations: number of pulmonary exacerbations compared with tobramycin (moderate certainty).
1 finding from 1 review
QoL · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Survival: number of deaths · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: colistimethate dry powder for inhalation… showed no clear difference in survival: number of deaths compared with tobramycin (low certainty).
1 finding from 1 review
Antibiotic resistance: change in mean MIC50 and MIC90 at the end of the trial · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Adverse events: number of treatment related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Summary of findings: colistimethate dry powder for inhalation… may leads to higher adverse events: number of treatment related adverse events compared with tobramycin (low certainty).
1 finding from 1 review
FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review